Precision Oncology News: Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback

Jan 17, 2023 | staff reporter

NEW YORK – Lantern Pharma on Tuesday said it received feedback from the US Food and Drug Administration that it will use to submit an investigational new drug application for LP-184. The company further plans to begin studying the drug in a Phase I trial of patients with solid tumors, including cancers with DNA damage repair deficiency, in the second quarter of 2023.

The Dallas-based company requested a pre-IND meeting with the agency at the end of 2022 to gather feedback on its plans for LP-184. Based on the agency’s input, Lantern is optimistic it will be able to start a Phase I trial for LP-184 next quarter and begin enrolling patients with pancreatic cancer, malignant gliomas, and select solid tumors with DNA damage repair deficiency.

Read Full Text

_________________________________________________________

Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on childhood cancer by discovering, developing, and disseminating new scientific knowledge. Our mission consists of three key areas — research, clinical, and education.

Stay connected with the Greehey CCRI on Facebook, Twitter, LinkedIn, and Instagram.